Cyclophosphamide (Cy) is toxic to several important normal tissues including bone marrow (Anders & Kemp, 1961) , urothelium (Philips et al., 1961) , lung in mice and occasionally in man (Collis, 1980) , and at very high doses, cardiac muscle (Mills & Roberts, 1979) . This toxicity is dose related, and in mice the time of death after lethal dosage also depends on the dose administered. At doses of Cy of up to 450mgkg-1 our studies show that most deaths occur between days 3-10 post-treatment. This corresponds to the presence of Cy induced neutropenia and urothelial damage (personal observation). At this dosage however some later deaths are also seen from about day 20 onwards and this corresponds to the period of respiratory distress and histologically demonstrated lung damage . At doses of Cy >450mg kg-1, mice die within a few hours of treatment, and it has been suggested that these deaths are associated with cardiac damage (Kovacs & Steinberg, 1972) . Similar acute deaths have been observed in dogs and have been shown at necropsy to be associated with cardiac damage (O'Connell & Berenbaum, 1972) . Acute cardiac deaths occurring within a few days of very high dose Cy treatment have also been reported in man (Mills & Roberts, 1979) .
In this paper, we describe attempts to prevent these acute deaths associated with very high dose Cy by administering the drug in divided dosage. We also describe the effects of such treatment on CBA/lac mice immune suppressed by thymectomy at 4 weeks of age followed 4 weeks later by 9Gy whole body irradiation were used for human tumour xenograft studies. The mice were pre-treated with cytosine arabinoside 2 days before the total body irradiation in order to enhance bone marrow recovery, as previously described (Steel et al., 1978) .
Human tumour xenograft studies Two human small cell carcinoma xenografts HX69 and HX72 originally established from material obtained by surgical biopsy were used in these studies. The tumours were in early passage, from serial passages 6-14, and had been shown to retain their human histological and chromosomal characteristics, and to have therapeutic responses to cytotoxic drugs similar to that seen in the patients from which the original biopsies were obtained (Shorthouse et al., 1980) . At (Millar & McElwain, 1978) , and it can be seen that when a pre-treatment dose of Cy (50mgkg-1) was administered 4 days before the divided dose, survival was further prolonged and 2 mice remained alive 8 weeks later. Table II shows that only 4/15 pre-treated mice survived for 72 h after a dose of Cy 600mg kg-1 administered over 12 h, whereas all 15 pre-treated mice survived 72 h when the drug was administered over 24 h. Eight weeks after therapy 7 of the group which received the drug over 24 h remained alive Figure 4 shows tumour growth delay in human small cell carcinoma xenograft HX72 treated with Cy 300mgkg-1 either as a single injection or over a 24h period as described above (both groups were pre-treated with Cy 50mgkg-' 4 days earlier). No significant difference in tumour growth delay was seen between the two treatments. Seven out of 9 animals treated with single dose died compared with 5/9 treated with divided dosage. No complete tumour remissions were seen in animals treated with stat dosage compared with 3/15 complete tumour remissions treated by divided dosage. mechanism of this effect is uncertain but may reflect diminished cardiotoxicity. Kovacs & Steinberg (1972) have suggested that the respiratory distress associated with the acute deaths following treatment with very high doses of Cy is caused by cardiac damage and it is well established that similar deaths in dogs 6-8 h after treatment is associated with haemorrhagic necrosis of the myocardium (O'Connell & Berenbaum, 1974) . In man too, acute cardiac deaths have been reported within a few hours of treatment with doses of 220mgkg-1 or greater, and at least once with only 144mgkg-1 (Mills & Roberts, 1979) . Doses as low as 60mgkg-1 have been associated with a transient rise in cardiac enzymes and ECG changes (Buckner et al., 1974 (Millar & McElwain, 1978) .
Critically, no loss of anti-tumour efficacy was observed with divided dose scheduling against 2 human small cell carcinoma xenografts. Indeed there was the suggestion that such scheduling had an enhanced effect with 3 complete remissions for HX72 compared with none after single dose therapy. Thus this technique achieves an enhanced therapeutic ratio for Cy, first in that the same dosage can be administered with significantly less fatal toxicity but with at least as good anti-tumour effect, and second in that significantly larger doses with appropriate increase in anti-tumour effect can be administered before the same fatal toxicity is reached.
Recently there has been considerable interest in the clinical use of high dose Cy to treat several human tumour types including small cell lung cancer and ovarian cancer (Souhami et al., 1982,; Buckner et al., 1974) . We are hopeful that divided dose scheduling may be useful clinically, and a pilot study based on these experiments is now in progress (Smith et al., 1983) . 
